TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Inmune Bio ( (INMB) ) has issued an update.
On December 2, 2025, INmune Bio Inc. announced amendments to the employment agreements of its President and Chief Executive, David J. Moss, and its Chief Financial Officer, Cory Ellspermann. The amendments corrected errors in the original agreements dated November 26, 2025, adjusting Moss’s base salary to $454,000 per annum and his stock option grant to 750,000 shares, while Ellspermann’s base salary was restated to $240,000 per annum.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
Average Trading Volume: 461,687
Technical Sentiment Signal: Sell
Current Market Cap: $41.74M
Find detailed analytics on INMB stock on TipRanks’ Stock Analysis page.